Sarcoma,Soft Tissue Clinical Trial
Official title:
Low-dose Computer Tomography in Follow-up of High Grade Soft Tissue Sarcomas - a Prospective, Comparative Study
The goal of this interventional study is to compare sensitivity of regular chest x-ray to ultra-low-dose computed tomography to find pulmonary relapse in follow-up of soft tissue sarcoma. The main question[s] it aims to answer are: - Is ultra-low-dose computed tomography more sensitive than regular chest x-ray to find pulmonary relapse? - Does ultra-low-dose computed tomography detect the most fast-growing pulmonary metastases earlier than regular chest x-ray? Participants will have seven ultra-low-dose computed tomography imagings in addition to simultaneous routine protocol of chest x-rays. Participants therefore work as their own controls.
After primary treatment with curative intent for soft tissue sarcoma, patients fulfilling the inclusion criteria and giving informed consent are enrolled. In study protocol patients have their regular chest x-ray once in two months plus ultra-low-dose computed tomography imaging is repeated seven times during the first two years of follow-up. After two years patients without detectable metastases continue in regular follow-up program. The aims of this prospective comparative study are to investigate whether ultra-low-dose computed tomography is more accurate than chest x-ray in soft tissue sarcoma and especially whether the most fast-growing pulmonary metastases could be detected earlier. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06114004 -
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
|
Phase 2 | |
Completed |
NCT01949506 -
(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
|
N/A | |
Recruiting |
NCT04595994 -
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma
|
Phase 1 | |
Recruiting |
NCT05235100 -
Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma
|
Phase 2 | |
Completed |
NCT04991883 -
Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities
|
||
Recruiting |
NCT04122872 -
GISAR German Interdisciplinary Sarcoma Registry
|
||
Recruiting |
NCT04910126 -
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT04219202 -
Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion
|
N/A | |
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Recruiting |
NCT05886634 -
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
|
Phase 2 | |
Recruiting |
NCT05167994 -
Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma
|
Phase 2 | |
Recruiting |
NCT04673942 -
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05813327 -
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04172805 -
Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
|
Phase 2 | |
Active, not recruiting |
NCT04887298 -
Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03600649 -
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
|
Phase 1 | |
Recruiting |
NCT05894018 -
Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT06263231 -
A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
|
Phase 3 | |
Completed |
NCT01985295 -
Combined Modality Treatment of Sarcomas of the Extremities
|
Phase 1 |